Leave it to the GOP to always look out for the little guy:
An effort to severely restrict pharmaceutical industry deals from delaying the entry to the market of low-cost generic drugs appears likely to die in the lame-duck. That could kill the legislation for some time, since a Republican House is seen as unlikely to support the measure.
A provision in the bill would get cheaper, generic drugs on the market more quickly.
This couldn’t be about profits over people again, could it? What? Nahhhh:
At the heart of the so-called “pay-for-delay” deals are brand name drug makers’ interest in holding onto lucrative patents for as long as possible.
To hell with affordability, patient care, the health of a nation. Hang on to those patents, Big Pharma, because that’s all that matters.
The Congressional Budget Office said the bill would save the government about $2.5 billion over 10 years, while the FTC – a strong proponent of limiting pay-for-delay agreements – estimated a ban on the agreements would save consumers at least $3.5 billion each year.
Now where did I put my dad’s Amlodipine Besylate? He’ll need it even more than ever.